Pathology: la/mBC - HR-positive - 1st line (L1);
la/mBC - HR-positive - 1st line (L1) | |||||||
MONARCH 3, 2017 | MonarchE, 2021 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | MONALEESA-2, 2016 | ||
palbociclib plus letrozole | 2 | T1 | T1 | ||||
abemaciclib plus endocrine therapy | 1 | T1 | |||||
palbociclib plus endocrine therapy | 1 | T1 | |||||
abemaciclib plus aromatase inhibitor | 1 | T1 | |||||
ribociclib plus letrozole | 1 | T1 | |||||
endocrine therapy | 0 | T0 | T0 | ||||
aromatase inhibitor | 0 | T0 | |||||
letrozole | 0 | T0 | T0 | T0 |